Investigational drug · Phase 2
PIPE-307
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsing Remitting Multiple Sclerosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "PIPE-307"
First trial start
2023
Nov 6, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PIPE-307", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsing Remitting Multiple Sclerosis
Approved drugs for the same conditions: Multiple sclerosis · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "PIPE-307" as an intervention, largest first.
- Study to Evaluate the Safety and Efficacy of PIPE-307 in Subjects With Relapsing-Remitting Multiple SclerosisPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06083753 · 182 participants · Start Nov 6, 2023 · Primary completion Jul 14, 2025
Drug: PIPE-307 Dose A; PIPE-307 Dose B and 1 more · For: Relapsing Remitting Multiple Sclerosis
Sites: Phoenix, Arizona; Berkeley, California; Colorado Springs, Colorado · 21 sites in all
Contineum TherapeuticsIndustry
NCT04725175 · 70 participants · Start Feb 26, 2021 · Primary completion Sep 1, 2021
Drug: PIPE-307; Placebo oral tablet · For: Multiple Sclerosis
Sites: Nedlands, Australia
Contineum TherapeuticsIndustry
NCT04941781 · 6 participants · Start Sep 1, 2021 · Primary completion Nov 10, 2021
Drug: PIPE-307 · For: Multiple Sclerosis
Sites: London, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Next-Generation Pharmacotherapies for Unipolar Mood Disorders: A Leading Article on Phase II/III Drug Development Across Diverse Mechanisms.
King A, Hardy M, Rhee TG, et al. · CNS Drugs 2026
- Targeting the muscarinic M1 receptor with a selective, brain-penetrant antagonist to promote remyelination in multiple sclerosis.
Poon MM, Lorrain KI, Stebbins KJ, et al. · Proc Natl Acad Sci U S A 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Johnson & Johnson (Janssen).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.